These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

960 related items for PubMed ID: 29400475

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA, Benešová M, Schibli R, Müller C.
    Mol Pharm; 2018 Jun 04; 15(6):2297-2306. PubMed ID: 29684274
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.
    Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, Colpo N, Lin KS, Bénard F.
    Mol Pharm; 2018 Nov 05; 15(11):5183-5191. PubMed ID: 30251544
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
    Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, Bénard F.
    J Nucl Med; 2021 Apr 05; 62(4):521-527. PubMed ID: 32859704
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development of 18F-Fluoroglycosylated PSMA-Ligands with Improved Renal Clearance Behavior.
    Potemkin R, Strauch B, Kuwert T, Prante O, Maschauer S.
    Mol Pharm; 2020 Mar 02; 17(3):933-943. PubMed ID: 32011889
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression.
    Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T, Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X.
    Eur J Nucl Med Mol Imaging; 2023 Jul 02; 50(9):2846-2860. PubMed ID: 37097443
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Synthesis and Evaluation of 68Ga- and 177Lu-Labeled (R)- vs (S)-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives.
    Zhao R, Ploessl K, Zha Z, Choi S, Alexoff D, Zhu L, Kung HF.
    Mol Pharm; 2020 Dec 07; 17(12):4589-4602. PubMed ID: 33108189
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy.
    Tschan VJ, Busslinger SD, Bernhardt P, Grundler PV, Zeevaart JR, Köster U, van der Meulen NP, Schibli R, Müller C.
    J Nucl Med; 2023 Oct 07; 64(10):1625-1631. PubMed ID: 37442604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.